» Articles » PMID: 34195286

Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2021 Jul 1
PMID 34195286
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Among the primary causes of cancer-associated death in the world, liver hepatocellular carcinoma (LIHC) ranks the third. LIHC is defined as the sixth most frequently diagnosed carcinoma. The gene mitochondrial carrier 1 (MTCH1) is a protein-coding gene. Recent research suggests that MTCH1 may be associated with some diseases. Here, our study attempts to explore the role and implication of MTCH1 in LIHC. Kaplan Meier Plotter and GEPIA (Gene Expression Profiling Interactive Analysis) databases were employed to determine the expression of MTCH1 and its correlation with prognostic status in LIHC patients. For the first time, our results suggested that MTCH1 was aberrantly expressed in human pan-cancer and highly expressed in LIHC. Its high expression was closely associated with metastasis of tumor, stage of cancer, and poor survival of patients. Then, through enrichment analysis, MTCH1 was found to be closely related to RNA splicing in LIHC. Subsequently, we conducted a series of functional experiments. PCR data showed that LIHC cell lines and samples are highly expressed MTCH1. CCK-8 (Cell Counting Kit-8) assays and Transwell assays indicated that silencing MTCH1 certainly suppressed cell proliferation, migration, and invasion. These findings shed the clue that MTCH1 could be regarded as the potential prognosis biomarker of LIHC and a promising therapeutic target for LIHC.

Citing Articles

Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth.

Zhao Y, Wu S, Cao G, Song P, Lan C, Zhang L Cell Death Dis. 2025; 16(1):95.

PMID: 39948081 PMC: 11825924. DOI: 10.1038/s41419-025-07419-0.


Analysis of Common Genetic Variation of Anxiety Disorders in Essential Tremor.

Yan Y, Cao L, Gu L, Xu C, Lu J, Lv D J Mol Neurosci. 2025; 75(1):14.

PMID: 39890685 DOI: 10.1007/s12031-024-02226-2.


Predictive model using four ferroptosis-related genes accurately predicts gastric cancer prognosis.

Wang L, Gong W World J Gastrointest Oncol. 2024; 16(5):2018-2037.

PMID: 38764813 PMC: 11099433. DOI: 10.4251/wjgo.v16.i5.2018.


Mitochondrial carrier homolog 2 increases malignant phenotype of human gastric epithelial cells and promotes proliferation, invasion, and migration of gastric cancer cells.

Zhang J, Huang L, Li Y, Tian Y, Yu J, Wang X World J Gastrointest Oncol. 2024; 16(3):991-1005.

PMID: 38577443 PMC: 10989370. DOI: 10.4251/wjgo.v16.i3.991.


AFB1 Triggers Lipid Metabolism Disorders through the PI3K/Akt Pathway and Mediates Apoptosis Leading to Hepatotoxicity.

Wang T, Li X, Liao G, Wang Z, Han X, Gu J Foods. 2024; 13(1).

PMID: 38201191 PMC: 10778638. DOI: 10.3390/foods13010163.


References
1.
Gu C, Shi X, Dang X, Chen J, Chen C, Chen Y . Identification of Common Genes and Pathways in Eight Fibrosis Diseases. Front Genet. 2021; 11:627396. PMC: 7844395. DOI: 10.3389/fgene.2020.627396. View

2.
Yang L, Xu J, Ou D, Wu W, Zeng Z . Hepatectomy for huge hepatocellular carcinoma: single institute's experience. World J Surg. 2013; 37(9):2189-96. DOI: 10.1007/s00268-013-2095-5. View

3.
Vural B, Sehitoglu E, Cavus F, Yalcinkaya N, Haytural H, Kucukerden M . Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. J Neuroimmunol. 2013; 263(1-2):139-44. DOI: 10.1016/j.jneuroim.2013.08.007. View

4.
Gu C, Pan X, Wang R, Li Y, Shen X, Shi J . Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component. Oncotarget. 2016; 7(17):24596-603. PMC: 5029726. DOI: 10.18632/oncotarget.8258. View

5.
Gu C, Chen J, Dang X, Chen C, Huang Z, Shen W . Hippo Pathway Core Genes Based Prognostic Signature and Immune Infiltration Patterns in Lung Squamous Cell Carcinoma. Front Oncol. 2021; 11:680918. PMC: 8117235. DOI: 10.3389/fonc.2021.680918. View